Summary: In middle-aged women diagnosed with prediabetes, vitamin D supplementation according to the study protocol demonstrated significantly improved insulin secretion compared to placebo control group without vitamin D supplementation, with no significant effects on fasting blood sugar, lipid profiles, anthropometric indices, or body composition.
| PICO | Description |
|---|---|
| Population | Middle-aged women diagnosed with prediabetes. |
| Intervention | Vitamin D supplementation according to the study protocol. |
| Comparison | Placebo control group without vitamin D supplementation. |
| Outcome | Vitamin D supplementation significantly improved insulin secretion but did not significantly affect fasting blood sugar, lipid profiles, anthropometric indices, or body composition. |
Vitamin D in prediabetic women
RCT · prediabetes · 12 weeks
Vitamin D raised insulin secretion and beta-cell function (HOMA-β) versus placebo, but did not change fasting glucose, lipids, or body composition.
Clinical Context
Vitamin D deficiency affects an estimated one billion people worldwide and has been epidemiologically linked to diabetes risk. However, observational associations don’t prove causation, and the mechanism by which vitamin D might influence glucose metabolism remains debated.
Middle-aged women with prediabetes represent a high-priority population for diabetes prevention. The menopausal transition brings metabolic changes that increase diabetes risk, including shifts in body composition and insulin sensitivity.
This randomized controlled trial tested whether vitamin D supplementation could improve metabolic parameters in this vulnerable population.
Clinical Pearls
1. Improved Insulin Secretion Without Improved Glucose: Enhanced beta-cell function should theoretically improve glucose control, but the finding may indicate that improved secretion compensates for existing insulin resistance without lowering glucose further.
2. Vitamin D Is Not a Weight Loss Intervention: The null findings for anthropometric indices and body composition confirm that vitamin D supplementation does not produce weight loss despite theoretical effects on adipokines.
3. This Aligns with the Larger Evidence Base: Most randomized trials of vitamin D for diabetes prevention have been negative for major clinical endpoints, including the large D2d trial.
4. Modest Benefits May Still Matter for Some: Individuals with severe vitamin D deficiency may derive greater metabolic benefit than those with mild insufficiency.
Practical Application
Vitamin D supplementation should not be positioned as a primary diabetes prevention strategy. Lifestyle intervention with modest weight loss and increased physical activity remains the cornerstone of prediabetes management.
However, checking vitamin D status in prediabetic patients is reasonable, and correcting deficiency is appropriate for bone health and general wellness. A reasonable target is 30-40 ng/mL (75-100 nmol/L).
Broader Evidence Context
The D2d trial found that vitamin D3 at 4,000 IU daily did not significantly reduce diabetes incidence compared to placebo in adults with prediabetes. The overall conclusion from the evidence base is that vitamin D may have minor metabolic effects but is not a clinically meaningful intervention for diabetes prevention in most individuals.
Study Limitations
Specific vitamin D dose and duration not reported in abstract. Sample size may have been insufficient for glucose endpoints. Baseline vitamin D status not characterized. Single-sex population limits generalizability to men.
Bottom Line
Vitamin D supplementation improves insulin secretion in middle-aged women with prediabetes but does not translate into improvements in fasting glucose, lipids, or body composition. Lifestyle intervention remains essential for diabetes prevention.
Source: Molani-Gol R, et al. “Effects of vitamin D supplementation on metabolic factors, serum omentin-1, and anthropometric indices in middle-aged women with prediabetes: a double-blind randomized controlled trial.” Read article.